RxDoctor Payments Data

Linda Melerine

Family · Slidell, LANPI 1992925242

Payments from drug & device makers

$9,485in general payments, 2019–2025

Across 550 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Novo Nordisk$1K
  • AbbVie$793
  • AstraZeneca$595
  • Pfizer$509
  • Lilly USA, LLC$478
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$9,26098%
  • Education$1652%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,485 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$44,637
Medicare patients
194
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide192$218,221
MounjaroTirzepatide160$187,478
EliquisApixaban156$141,042
JardianceEmpagliflozin114$120,047
Trelegy ElliptaFluticasone/Umeclidin/Vilanter130$110,442
FarxigaDapagliflozin Propanediol80$66,904
TrulicityDulaglutide45$52,271
MyrbetriqMirabegron62$38,371
LinzessLinaclotide30$35,636
XareltoRivaroxaban38$35,412
GemtesaVibegron45$32,838
RybelsusSemaglutide20$27,706
VascepaIcosapent Ethyl42$26,877
JanuviaSitagliptin Phosphate22$23,783
Soliqua 100-33Insulin Glargine/Lixisenatide27$22,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,073$245,927212 claims
Lilly USA, LLCMounjaro, Trulicity$478$239,749205 claims
PfizerEliquis$509$141,042156 claims
Boehringer IngelheimJardiance, Tradjenta$166$135,125128 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,781$125,399157 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$595$96,473130 claims
MerckJanuvia, Belsomra, Janumet$230$40,37052 claims
Astellas Pharma US IncMyrbetriq$434$38,37162 claims
AbbVieLinzess$793$35,63630 claims
Johnson & JohnsonXarelto$99$35,41238 claims
Sumitomo Pharma America, Inc.Gemtesa$83$32,83845 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$139$22,57527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →